Quantcast

Latest Myocardial perfusion imaging Stories

2008-10-06 12:00:12

By Strauss, H William; Miller, D Douglas; Wittry, Mark D; Cerqueira, Manuel D; Garcia, Ernest V; Iskandrian, Abdulmassi S; Schelbert, Heinrich R; Wackers, Frans J; Balon, Helena R; Lang, Otto; Machac, Josef I. PURPOSE The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of myocardial perfusion imaging studies. II. BACKGROUND INFORMATION AND DEFINITIONS Myocardial perfusion imaging uses an...

2008-09-23 15:00:34

Bracco Diagnostics Inc., the US-based subsidiary of Bracco Imaging SpA and part of the Bracco Group, and Lantheus Medical Imaging, Inc., both worldwide leaders in diagnostic imaging, announced today that the companies have entered into an agreement for Lantheus to co-promote Bracco's CardioGen-82(R) (Rubidium Rb 82 Generator), a myocardial perfusion Positron Emission Tomography (PET) imaging agent. CardioGen-82 is the only generator-based PET perfusion agent approved by the U.S. Food and Drug...

2008-09-13 12:00:00

To: MEDICAL EDITORS Contact: Beth Hodge, +1-240-429-9983, bhodge@asnc.org, or Steve Carter, +1-301-802-7100, scarter@asnc.org, both of the American Society of Nuclear Cardiology BOSTON, Sept. 13 /PRNewswire-USNewswire/ -- Cardiovascular disease kills more women each year than all cancers combined. Although this statistic is gaining more recognition among physicians and patients, the unique risk factors and symptoms of female patients make diagnosis and prognosis of women with heart...

2008-09-13 12:00:00

To: MEDICAL EDITORS Contact: Beth Hodge, +1-240-429-9983, bhodge@asnc.org, or Steve Carter, +1-301-802-7100, scarter@asnc.org, both of the American Society of Nuclear Cardiology BOSTON, Sept. 13 /PRNewswire-USNewswire/ -- There are 21 million patients with Type 2 diabetes in the United States alone. Coronary artery disease (CAD) is a major cause of morbidity in patients with diabetes. Silent myocardial ischemia is common, and cardiac death or myocardial infarction may be the first...

2008-09-13 03:00:10

By De Winter, O Van De Veire, N; De Bondt, P; Van De Wiele, C; De Buyzere, M; De Backer, G; Gillebert, T C; Dierckx, R A; De Sutter, J Aim. The aim of this study was to investigate the prognostic value of myocardial perfusion and function SPECT imaging in patients with coronary artery disease (CAD) and poor left ventricular (LV) function. Methods. We studied 261 patients (231 men, age 66+-10 years) with CAD and a resting LV ejection fraction (LVEF) =40% assessed during myocardial gated...

2008-07-24 12:01:22

QuantRx Biomedical has announced that the company's FluoroPharma has achieved positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging. The Phase I trial was designed to evaluate safety, distribution and dosimetry of BFPET in 12 healthy subjects following a single dose injection at rest. BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical development. BFPET is a positron emission tomography (PET) imaging...

2008-07-23 12:01:24

BOSTON, July 23 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging. BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical development. BFPET is a PET imaging agent, designed to assess the blood flow in the heart (myocardial perfusion). Myocardial...

2008-07-23 12:01:24

QuantRx(R) Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that QuantRx's FluoroPharma has achieved positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging. BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical...

2008-06-17 09:01:13

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today presents Phase I data relating to the safety and tolerability in human subjects of BMS747158, its novel fluorine 18-labeled Positron Emission Tomography (PET) tracer for myocardial perfusion imaging. The presentation was made by the Principal Investigator, Dr. Jamshid Maddahi, at the 55th Annual Meeting of the SNM in New Orleans, Louisiana. The preliminary clinical findings indicate that when used with PET...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related